Abstract
CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to construct vaccines for B-cell-related disorders. The immunogenicity of the vaccines was tested in BALB/c mice. Results of this study suggest that the mimotope may be a useful tool for the construction of a functional vaccine to treat B cell-related disorders.
Keywords: CD20, mimotope, vaccine, B-cell lymphoma, immunotherapy, keyhole limpet hemocyanin (KLH)
Protein & Peptide Letters
Title: Development of a Mimotope-Based Vaccine Against CD20 Antigen
Volume: 14 Issue: 6
Author(s): Meng Li, Wei Han, Quiyang Zhang, Xiaochang Xue, Zenglu Wang and Yingqi Zhang
Affiliation:
Keywords: CD20, mimotope, vaccine, B-cell lymphoma, immunotherapy, keyhole limpet hemocyanin (KLH)
Abstract: CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to construct vaccines for B-cell-related disorders. The immunogenicity of the vaccines was tested in BALB/c mice. Results of this study suggest that the mimotope may be a useful tool for the construction of a functional vaccine to treat B cell-related disorders.
Export Options
About this article
Cite this article as:
Meng Li , Wei Han , Quiyang Zhang , Xiaochang Xue , Zenglu Wang and Yingqi Zhang , Development of a Mimotope-Based Vaccine Against CD20 Antigen, Protein & Peptide Letters 2007; 14 (6) . https://dx.doi.org/10.2174/092986607780989958
DOI https://dx.doi.org/10.2174/092986607780989958 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy Preface
Current Pediatric Reviews Overcoming the Challenges of siRNA Delivery: Nanoparticle Strategies
Current Drug Delivery Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Role of IL-10 in the Resolution of Airway Inflammation
Current Molecular Medicine Malignant Hypercalcemia
Current Medicinal Chemistry Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design Towards the Development of Tumor Necrosis Factor (TNF) Sensitizers:Making TNF Work Against Cancer
Current Pharmaceutical Design Cellular Toxicity and Apoptosis Studies in Osteocarcinoma Cells, a Comparison of 177Lu-EDTMP and Lu-EDTMP
Current Radiopharmaceuticals A Hybrid Discrete Imperialist Competition Algorithm for Gene Selection for Microarray Data
Current Proteomics Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences The Role of Wnt/Beta-Catenin Signaling in Renal Carcinogenesis: Lessons from Cadmium Toxicity Studies
Current Molecular Medicine Medicinal Properties of the Jamaican Pepper Plant Pimenta dioica and Allspice
Current Drug Targets Neuregulin Signaling in Pieces-Evolution of the Gene Family
Current Pharmaceutical Design Endocrine and Antineoplastic Actions of Growth Hormone-Releasing Hormone Antagonists
Current Medicinal Chemistry Cisplatin Analogues with an Increased Interaction with DNA: Prospects for Therapy
Current Pharmaceutical Design Vinyl Azides as Versatile Synthons for the Synthesis of Nitrogen-containing Heterocycles
Current Organic Chemistry Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development
Current Angiogenesis (Discontinued)